基于预后亚组定制效用的精准贝叶斯I-II期剂量探索
提出一种贝叶斯I-II期设计,在预设预后亚组内优化新药剂量,并以转移性透明细胞肾癌试验为背景。设计联合建模随访期毒性时间与随访末有序疗效,对相邻相似亚组自适应聚类以借用信息,并按亚组分别诱导效用权衡风险获益。模拟研究评价其可靠性、安全性与稳健性,并与忽略亚组或各亚组独立试验的设计比较。
要点
- 按预后亚组分别诱导效用,可体现亚组间风险获益权衡差异。
- 对相邻相似亚组自适应聚类,有助于跨亚组借用剂量-结局信息。
- 同时建模毒性时间与有序疗效两个临床结局。
核心结论
- 所提贝叶斯I-II期设计可在预设预后亚组内优化新药剂量,并允许亚组间风险获益权衡不同。
研究设计与样本
- 为贝叶斯I-II期剂量探索设计,以转移性透明细胞肾癌靶向治疗试验为动机。
- 剂量探索使用两个临床结局:预设随访期内的毒性时间与随访末有序疾病状态表征的疗效。
- 构建结局关于剂量与亚组的联合概率模型,并对相邻且剂量-结局分布相似的亚组进行自适应聚类。
主要发现
- 模拟研究评价了设计的可靠性、安全性与稳健性。
- 模拟研究将所提设计与忽略亚组的设计、以及每个亚组内单独开展试验的设计进行比较。
临床怎么用
- 在具有既定预后风险评分的亚组人群中,可考虑按亚组分别设定效用并自适应聚类相邻亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A Bayesian phase I-II design is presented that optimizes the dose of a new agent within predefined prognostic subgroups. The design is motivated by a trial to evaluate targeted agents for treating metastatic clear cell renal carcinoma, where a prognostic risk score defined by clinical variables and biomarkers is well established. Two clinical outcomes are used for dose-finding, time-to-toxicity during a prespecified follow-up period, and efficacy characterized by ordinal disease status evaluated at the end of follow-up. A joint probability model is constructed for these outcomes as functions of dose and subgroup. The model performs adaptive clustering of adjacent subgroups having similar dose-outcome distributions to facilitate borrowing information across subgroups. To quantify toxicity-efficacy risk-benefit trade-offs that may differ between subgroups, the objective function is based on outcome utilities elicited separately for each subgroup. In the context of the renal cancer trial, a design is constructed and a simulation study is presented to evaluate the design's reliability, safety, and robustness, and to compare it to designs that either ignore subgroups or run a separate trial within each subgroup.
引用
- Lee J, Thall PF, Msaouel P, et al. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med. 2021. PMID: 34636054. doi:10.1002/sim.9120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。